Xarelto

Deep Vein Thrombosis (DVT), prophylaxis of systemic embolism, Deep Vein Thrombosis + 20 more
Treatment
22 FDA approvals
20 Active Studies for Xarelto

What is Xarelto

RivaroxabanThe Generic name of this drug
Treatment SummaryRivaroxaban is a blood-thinning medication. It is the first of its kind that can be taken orally and works by stopping the body's natural formation of blood clots. Unlike other anticoagulants, Rivaroxaban does not require regular tests to monitor its effectiveness. However, there is no antidote available if a person experiences excessive bleeding. The 10 mg tablet can be taken without food, while the 15 mg and 20 mg tablets should be taken with food. Rivaroxaban was approved by the FDA in 2011.
Xareltois the brand name
image of different drug pills on a surface
Xarelto Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xarelto
Rivaroxaban
2011
15

Approved as Treatment by the FDA

Rivaroxaban, otherwise called Xarelto, is approved by the FDA for 22 uses like Recurrent Pulmonary Embolism (Disorder) and Peripheral Arterial Disease (PAD) .
Recurrent Pulmonary Embolism (Disorder)
Peripheral Arterial Disease (PAD)
Used to treat Peripheral Arterial Disease (PAD) in combination with Acetylsalicylic acid
Prophylaxis of Deep Vein Thrombosis
Chronic Coronary Artery Disease
Used to treat Chronic Coronary Artery Disease in combination with Acetylsalicylic acid
Non Valvular Atrial Fibrillation (nv AF)
Deep Vein Thrombosis
Deep vein thrombosis recurrent
Deep Vein Thrombosis
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Acetylsalicylic acid
Cerebrovascular accident prophylaxis
Total Knee Arthroplasty
Arthroplasty
Heart Attack
Used to treat Myocardial Infarction in combination with Acetylsalicylic acid
Disease
Stroke
Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid
Systemic Embolism
Peripheral Arterial Disease
Used to treat Peripheral Arterial Disease (PAD) in combination with Acetylsalicylic acid
Coronary Artery Disease
Used to treat Chronic Coronary Artery Disease in combination with Acetylsalicylic acid
prophylaxis of systemic embolism
Atrial Fibrillation
Deep Vein Thrombosis
Pulmonary Embolism

Effectiveness

How Xarelto Affects PatientsRivaroxaban is a medication that stops blood from clotting. It works by blocking a protein (called Factor Xa) that helps start the process of forming a blood clot. Rivaroxaban is different from other anticoagulants because it is taken orally, not injected, and it does not need another protein (called antithrombin III) to work. Testing the levels of rivaroxaban in the blood is not recommended as it does not give an accurate measure of how well the drug is working.
How Xarelto works in the bodyRivaroxaban stops the formation of blood clots by blocking a protein called factor Xa from activating. Factor Xa is needed to turn prothrombin into thrombin, which helps form a loose meshwork in the clotting process. Rivaroxaban prevents this process from happening, making it difficult for a clot to form. The effects of rivaroxaban are irreversible.

When to interrupt dosage

Condition
Dosage
Administration
Deep Vein Thrombosis (DVT)
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
prophylaxis of systemic embolism
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Deep Vein Thrombosis
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Cerebrovascular accident prophylaxis
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Total Knee Arthroplasty
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Congenital Heart Defect
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Arthroplasty
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Peripheral Arterial Disease
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Coronary Disease
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Heart Attack
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Pulmonary Embolism
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Fontan Procedure
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Stroke
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Major Adverse Cardiovascular Events
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Deep Vein Thrombosis
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Coronary Artery Disease
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Acute Coryza
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Systemic Embolism
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Prophylaxis of Venous Thromboembolic Events
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule
Atrial Fibrillation
, 10.0 mg, 15.0 mg, 20.0 mg, 2.5 mg, 5250.0 mg, 2625.0 mg, 1.0 mg/mL, 51.7 mg, 103.4 mg, 155.0 mg
Tablet, , Tablet - Oral, Oral, Tablet, film coated - Oral, Tablet, film coated, Kit; Tablet, Kit; Tablet - Oral, Granule, for suspension, Granule, for suspension - Oral, Granule - Oral, Granule

Warnings

Xarelto Contraindications
Condition
Risk Level
Notes
Hemorrhage
Do Not Combine
There are 20 known major drug interactions with Xarelto.
Common Xarelto Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Rivaroxaban.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Rivaroxaban.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Rivaroxaban.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Rivaroxaban.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Rivaroxaban.
Xarelto Toxicity & Overdose RiskTaking too much of this drug can cause excessive bleeding. Treatment may include activated charcoal and other measures to help stop the bleeding. If the bleeding does not stop, a doctor may give procoagulants, such as activated prothrombin complex concentrate, prothrombin complex concentrate, or recombinant factor VIIa. People who take this drug may also have a higher chance of post-procedure bleeding compared to those taking enoxaparin.
image of a doctor in a lab doing drug, clinical research

Xarelto Novel Uses: Which Conditions Have a Clinical Trial Featuring Xarelto?

206 active trials are presently being conducted to assess the effectiveness of Xarelto in Total Knee Replacement, Recurrent Venous Thromboembolism and Deep Vein Thrombosis interventions.
Condition
Clinical Trials
Trial Phases
prophylaxis of systemic embolism
0 Actively Recruiting
Cerebrovascular accident prophylaxis
0 Actively Recruiting
Coronary Disease
1 Actively Recruiting
Not Applicable
Deep Vein Thrombosis
0 Actively Recruiting
Deep Vein Thrombosis (DVT)
31 Actively Recruiting
Phase 4, Not Applicable, Early Phase 1, Phase 3, Phase 2, Phase 1
Coronary Artery Disease
0 Actively Recruiting
Arthroplasty
3 Actively Recruiting
Not Applicable
Acute Coryza
0 Actively Recruiting
Pulmonary Embolism
22 Actively Recruiting
Early Phase 1, Phase 4, Phase 3, Not Applicable
Peripheral Arterial Disease
36 Actively Recruiting
Not Applicable, Phase 3, Phase 1, Early Phase 1, Phase 2, Phase 4
Stroke
6 Actively Recruiting
Not Applicable, Phase 1
Heart Attack
23 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3
Systemic Embolism
2 Actively Recruiting
Not Applicable
Fontan Procedure
1 Actively Recruiting
Not Applicable
Venous Thromboembolism
0 Actively Recruiting
Major Adverse Cardiovascular Events
0 Actively Recruiting
Congenital Heart Defect
27 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1
Disease
0 Actively Recruiting
Prophylaxis of Venous Thromboembolic Events
1 Actively Recruiting
Phase 1
Deep Vein Thrombosis
9 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 4

Xarelto Reviews: What are patients saying about Xarelto?

5Patient Review
9/6/2022
Xarelto for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation
I haven't had any of the side effects mentioned by other people on this site. I would rather take this medication than risk a blood clot resulting in stroke or death.
5Patient Review
9/13/2019
Xarelto for Deep Vein Thrombosis Prevention
I had a pulmonary embolism and started this treatment six years ago. I have not experienced any negative side effects from it.
5Patient Review
5/14/2022
Xarelto for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation
I've been using this medication for three months now and I couldn't be happier. No side effects whatsoever.
5Patient Review
11/2/2020
Xarelto for Treatment to Prevent Recurrence of a Clot in a Deep Vein
There are no adverse effects to taking this medication. I would recommend doing so at bedtime. Whenever I have cut myself while on this medication, the bleeding has been minimal.
4.3Patient Review
9/3/2021
Xarelto for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation
I've been on Xarelto for half a year now, and it's kept the blood clot in my heart at bay. I haven't had any serious side effects that I know of, though there is an unusual rash on my forearm that won't go away. My doctor suggested a "Watchman" procedure if I want to stop taking this medication, but I'm not sure if that's the best idea.
4Patient Review
9/18/2019
Xarelto for Blood Clot in Lung
I've started having rashes and swellings on my limbs since I began taking this medication. My doctors thought it might be gout or arthritis, but since I never had any problems like this before starting to take Xarelto, I'm more inclined to believe that it's a side effect of the drug. My right leg has been swollen for ten days now.
3.7Patient Review
6/10/2019
Xarelto for Blood Clot in a Deep Vein
3Patient Review
3/24/2022
Xarelto for Treatment to Prevent a Blood Clot in the Lung
I have been experiencing a lot of pain in my legs and feet. Recently, it has started to affect my arms and neck as well. I've had check-ups for everything possible, but sadly I think it might be the Xeralto. I won't touch it ever again; the pain and weakness is unreal. I hope it eventually stops...
3Patient Review
3/15/2020
Xarelto for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation
Xarelto has been nothing but trouble for me. It's given me joint pain and made it difficult to move around.
2.3Patient Review
11/10/2020
Xarelto for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation
My husband died from a brain hemorrhage after taking this drug. Please, do not use it.
2Patient Review
11/16/2021
Xarelto for Blood Clot in Lung
I had to stop taking this medication before finishing the course due to strong side effects. Even now, six months later, I'm still experiencing nausea, loss of appetite, and a burning sensation in my stomach.
2Patient Review
11/21/2019
Xarelto for Blood Clot in Lung
I was experiencing pain and weakness in both of my legs when I tried this treatment.
1Patient Review
6/9/2022
Xarelto for Myocardial Reinfarction Prevention
I tried this medication for atrial fibrillation. The first pill resulted in the next day waking up to a total loss of use of my left leg. The second pill then caused a total loss of use of my right leg. That's all I took before quitting; and fortunately, after discontinuing usage my leg function returned. However, subsequent to this experience, my physical therapy was extended for 3 months - so it's clear that insurance companies are aware of these types of side effects from the drug.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xarelto

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the serious side effects of Xarelto?

"The following are symptoms of cervical cancer: back pain, bloody stools, bowel or bladder dysfunction, burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings, coughing up blood, difficulty with breathing or swallowing, headache, increased menstrual flow or vaginal bleeding."

Answered by AI

What is better eliquis or Xarelto?

"Medication A (apixaban/Eliquis) is better than medication B (rivaroxaban/Xarelto) for stroke prevention in patients with atrial fibrillation, according to a study published in JAMA. Medication A was associated with reduced rates of severe bleeding complications and strokes."

Answered by AI

Why was Xarelto taken off the market?

"Xarelto also has a number of additional side effects, including abdominal bleeding, brain hemorrhage, abnormal liver function and reduced platelet levels. Janssen Pharmaceuticals issued a voluntary recall of 13,500 bottles of Xarelto last October due to a microbial contamination discovered in a sample."

Answered by AI

What is the most common side effect of Xarelto?

"Common side effects of Xarelto include bleeding. Xarelto is an anticoagulant drug that makes it harder for your body to form blood clots, so an increased risk for bleeding is to be expected."

Answered by AI

Why is Xarelto taken at night?

"XARELTO should be taken orally once daily with the evening meal."

Answered by AI

What is Xarelto used for?

"This can lead to blood clots, which can travel to the brain, causing a stroke, or to other parts of the body

XARELTO is a prescription medication used to reduce the risk of stroke and blood clots in adults who have a medical condition called atrial fibrillation."

Answered by AI

Clinical Trials for Xarelto

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA
The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
Phase 4
Waitlist Available
Inova Alexandria Hospital
Image of St.Joseph's Healthcare Hamilton in Hamilton, Canada.

Rivaroxaban + ASA for Hip Fracture

18+
All Sexes
Hamilton, Canada
A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.
Phase 3
Waitlist Available
St.Joseph's Healthcare Hamilton (+1 Sites)Federico Germini, Doctor of Medicine
Have you considered Xarelto clinical trials? We made a collection of clinical trials featuring Xarelto, we think they might fit your search criteria.Go to Trials
Image of SUNY Upstate in Syracuse, United States.

Apixaban or Enoxaparin for Head and Neck Cancer Surgery

18 - 89
All Sexes
Syracuse, NY
The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine? Researchers will compare 2 groups: One group will take apixaban (a pill taken twice a day) for 10 days after surgery. The other group will take enoxaparin (a shot given once a day) for 10 days after surgery. Participants will: Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks How long will participation last? About 4 months from surgery through the last follow-up visit.
Phase 4
Recruiting
SUNY Upstate
Have you considered Xarelto clinical trials? We made a collection of clinical trials featuring Xarelto, we think they might fit your search criteria.Go to Trials
Image of Baystate Medical Center in Springfield, United States.

Consent Approaches for Heart Disease Rehabilitation

18+
All Sexes
Springfield, MA
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation. In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project. The two main goals of this study is to understand: 1. If the consent approach type impacts participation rates in the research study 2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.
Waitlist Available
Has No Placebo
Baystate Medical CenterQuinn R Pack, MD, MSc
Image of The Hospital for Sick Children in Toronto, Canada.

Peer Mentorship for Heart Disease

18 - 35
All Sexes
Toronto, Canada
Young adults with heart failure, including those who have undergone a heart transplant, experience considerable psychosocial stressors associated with living with a chronic illness, including heightened levels of anxiety and depression, and poor health-related quality of life compared to 'healthy' peers. Psychosocial challenges during young adulthood are especially concerning as this life stage represents a unique transitional period for fostering self-identity, friendships, mastery, and decision-making competencies. As young people with heart failure transition into adult healthcare systems, they take on greater personal responsibility due to their increasing independence and involvement in care decisions, and require more support and resources to live longer, healthier lives. Peer support provided by a person with a similar experience has been found to improve disease self-management and psychosocial health outcomes in pediatric healthcare. An established, online mentorship program, iPeer2Peer (iP2P), will be employed through a pilot feasibility waitlist randomized controlled trial with repeated measures across five sites. Sixty mentees will be recruited and randomized into intervention and control groups. Thirty mentees in the intervention group will be matched 1:1 with 20 trained mentors. These pairings will connect over 12 weeks through video calls and text messaging to provide peer support to improve self-management and psychosocial health outcomes.
Waitlist Available
Has No Placebo
The Hospital for Sick Children
Image of Brooks Rehabilitation Clinical Research Center in Jacksonville, United States.

Q Therapeutic System for Stroke

18 - 80
All Sexes
Jacksonville, FL
This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.
Recruiting
Has No Placebo
Brooks Rehabilitation Clinical Research CenterEmily Fox, PT, DPT, MHS, PhDBrainQ Technologies Ltd.
Image of Children's Hospital Los Angeles in Los Angeles, United States.

Parent Navigator Program for Congenital Heart Disease

Any Age
All Sexes
Los Angeles, CA
The goal of this clinical trial is to see if a Parent Navigator Program (PNP) is helpful for Latino/x parents of babies with congenital heart disease (CHD) to get connected to developmental follow-up services. The main question it aims to answer are: * Do families assigned to the Parent Navigator Program (PNP) have higher rates of connection to High-Risk Infant Follow-Up (HRIF)/Early Intervention (EI) compared to the standard care group 6 months after randomization? * Do children assigned to the Parent Navigator Program (PNP) have better neurodevelopmental outcomes (NDOs) compared to the standard care group 6 months after randomization? * Do parents assigned to the Parent Navigator Program (PNP) have decreased parental stress compared to the standard care group? Researchers will compare the Parent Navigator group to the standard care group to see if parent navigator group is helpful in connecting families to High-Risk Infant Follow-Up (HRIF)/Early Intervention (EI), improving neurodevelopmental outcomes (NDOs), and lowering parental stress. Participants will: * Undergo developmental assessments and survey at newborn stage and at 6 months * Participants randomly assigned to the Parent Navigator group will have weekly (at least) phone calls with the parent navigator * Participants randomly assigned to the Parent Navigator group will complete a 30-minute phone interview about their experience with the parent navigator program 6 months after random assignment
Recruiting
Has No Placebo
Children's Hospital Los AngelesNhu Tran, PhD, RN
Have you considered Xarelto clinical trials? We made a collection of clinical trials featuring Xarelto, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security